First Ozempic Generics in Canada Test Novo Nordisk's Global Pricing Power

What happened

Canada has approved the first generic versions of Ozempic, marking the beginning of international revenue erosion for Novo Nordisk's semaglutide franchise. This development comes as the company already faces intense US pricing pressure, having lost prescription leadership and volume market share in both obesity and diabetes GLP-1s. The Canadian generic entry validates the thesis that semaglutide's patent exclusivity is weakening, potentially accelerating revenue declines in other markets. While the base case already assumed some international price erosion, this concrete event shifts the risk profile toward the bear scenario. The next one to two quarters must show that telehealth and oral GLP-1 strategies can offset volume losses without further price concessions.

Implication

The Canadian generics test case will inform the pace of international erosion. If Novo's subscription and telehealth models can stabilize volumes at lower prices, the long-term impact may be manageable, but if generics spread quickly, the bear case (target $38) becomes more probable.

Thesis delta

The Canadian generic launch shifts the thesis's risk balance: international revenue declines are now a near-term reality, not just a tail risk. This increases the probability of the bear scenario (30% → 35-40%), where global pricing competition erodes margins faster than volume growth can compensate. The watch item is whether Novo can contain the damage to Canada or if it presages broader international patent challenges.